Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened
Corbus Pharmaceuticals Holdings, Inc. announced on March 9, 2026 that it issued a press release disclosing financial information and operating metrics for the fiscal year ended December 31, 2025 and discussing its business outlook. The disclosure was filed as an Item 2.02 (Results of Operations and Financial Condition) on Form 8-K.

Key Details

• Press release dated March 9, 2026 discloses fiscal year results and operating metrics for the year ended Dec. 31, 2025 (attached as Exhibit 99.1).
• An investor presentation was furnished with the report (Exhibit 99.2).
• Filing covers Item 2.02 (results of operations) and includes exhibit disclosures under Item 9.01.
• Form 8-K was signed by CEO Yuval Cohen.

Why It Matters
This 8-K signals that Corbus has provided its full-year 2025 financial results and management commentary, which are material for investors assessing recent revenue, earnings/expenses, cash position and company guidance. Retail investors should review the attached press release and investor presentation for the specific revenue, profit/loss, cash runway and any forward-looking statements or milestones disclosed by management. This filing does not report executive changes, mergers, or bankruptcy—only the company’s reported financial results and outlook.